Bladder Cancer at a Crossroads: Sequencing, Biomarkers, and Combination Therapy
Bladder Cancer at a Crossroads: Sequencing, Biomarkers, and Combination Therapy

An expert panel convened to discuss the evolving treatment and diagnostic landscape of NMIBC. Moderated by Sia Daneshmand, MD, University of Southern California, the roundtable consisted of Mark D. Tyson, MD, Mayo Clinic; Aaron Berger, MD, Associated Urological Specialists; and Vignesh T. Packiam, MD, Rutgers Cancer Institute.

In the first segment of the discussion, the panel discusses a wave of bladder cancer therapies—including cretostimogene, gem/doce, and AI-driven biomarkers—highlighting the excitement around new data, treatment sequencing, and the potential of combination strategies to improve bladder preservation.

Advertisement

Latest News

Redefining Quality of Life: The Future of Patient-Reported Outcomes
Redefining Quality of Life: The Future of Patient-Reported Outcomes
Elizabeth Wulff-Burchfield, MDProstate Cancer | May 15, 2025
Drs. Wulff-Burchfield and Beckermann offer perspective on how patient-driven science is shaping QOL measurement.
Reframing Cancer Treatment: Trust, Transparency, and the Human Side of Care
Reframing Cancer Treatment: Trust, Transparency, and the Human Side of Care
Elizabeth Wulff-Burchfield, MDProstate Cancer | May 15, 2025
Drs. Wulff-Burchfield and Beckermann share how they help GU patients make informed, personalized treatment decisions.
The Art of the Consult: Goals, Trade-offs, and Treatment in GU Oncology
The Art of the Consult: Goals, Trade-offs, and Treatment in GU Oncology
Elizabeth Wulff-Burchfield, MDProstate Cancer | May 15, 2025
Drs. Wulff-Burchfield and Beckermann discuss how GU oncologists can build trust and deepen patient connections.
Active Surveillance, MRI Can Aid in the Avoidance of Repeat Biopsies for Patients With Prostate Cancer
Active Surveillance, MRI Can Aid in the Avoidance of Repeat Biopsies for Patients With Prostate Cancer
Emily MenendezProstate Cancer Diagnostics | May 15, 2025
The use of MRI-based monitoring can aid in the avoidance of repeat biopsies, and reduce the chances of undergoing surgery.
Bladder Cancer Without Cystectomy: Dr. Alexandre Zlotta on the Maturation of Trimodality Therapy
Bladder Cancer Without Cystectomy: Dr. Alexandre Zlotta on the Maturation of Trimodality Therapy
Alexandre Zlotta, MDMuscle Invasive Urothelial Carcinoma | May 15, 2025
Dr. Zlotta discusses the current state and future of bladder-sparing therapy in MIBC, including how to best select patients.
Durvalumab Plus BCG May Improve Disease-Free Survival in Patients With NMIBC
Durvalumab Plus BCG May Improve Disease-Free Survival in Patients With NMIBC
Emily MenendezNon-Muscle Invasive Urothelial Carcinoma | May 14, 2025
Adding one year of treatment with durvalumab to BCG can extend the time that patients live without disease recurrence.
SNiP-RCC Study: Using Predictive Model to Determine Nivolumab Therapy for Treating Patients With Advanced RCC
SNiP-RCC Study: Using Predictive Model to Determine Nivolumab Therapy for Treating Patients With Advanced RCC
Jessica GangaAdvanced Renal Cell Carcinoma | May 14, 2025
Machine learning may be a useful tool in predicting renal cell carcinoma tumor response to nivolumab monotherapy.
InPACT Trial Seeks to Determine Best Treatment Sequencing for Penile Cancer
InPACT Trial Seeks to Determine Best Treatment Sequencing for Penile Cancer
Emily MenendezTesticular, Penile, and Rare Malignancies | May 8, 2025
Guidance addresses prepubic fat coverage and dose fractionation for both neoadjuvant and adjuvant settings.
TOMBOLA: Preliminary Results Show Promise for ctDNA-Guided Immunotherapy for Patients With MIBC
TOMBOLA: Preliminary Results Show Promise for ctDNA-Guided Immunotherapy for Patients With MIBC
Jessica GangaMuscle Invasive Urothelial Carcinoma | May 8, 2025
Researchers find promise for ctDNA-guided immunotherapy for patients with MIBC who underwent radical cystectomy.
From Detection to Decision: The Future of Bladder Cancer Follow-Up
From Detection to Decision: The Future of Bladder Cancer Follow-Up
Sia Daneshmand, MDUrothelial Carcinoma | May 8, 2025
The panel concludes with a discussion on the complexities of interpreting ctDNA positivity in earlier-stage bladder cancer.
Bladder Preservation and Precision: Biomarkers Guiding the Future
Bladder Preservation and Precision: Biomarkers Guiding the Future
Sia Daneshmand, MDUrothelial Carcinoma | May 8, 2025
The panel considers the adoption of bladder-sparing protocols and the potential of biomarkers to guide risk stratification.
Rethinking Risk: When to Repeat TURBT in Complex Bladder Cancer Cases
Rethinking Risk: When to Repeat TURBT in Complex Bladder Cancer Cases
Sia Daneshmand, MDUrothelial Carcinoma | May 8, 2025
The panel debates the management of high-grade T1 bladder cancer with lymphovascular invasion and variant histology.

The Uromigos Live and Unplugged 2024

The Uromigos Live & Unplugged 2024
The Uromigos Live & Unplugged 2024

The Uromigos Live & Unplugged 2024 took place September 27-29 in Nashville, Tennessee.

This meeting was the third annual in-person event hosted by Thomas Powles, MD, and Brian Rini, MD, FASCO, in partnership with Mashup Media, featuring expert panels and audience discussion around the latest data in genitourinary oncology and vision for the future.

Expert Interviews

Bladder Cancer Without Cystectomy: Dr. Alexandre Zlotta on the Maturation of Trimodality Therapy
Bladder Cancer Without Cystectomy: Dr. Alexandre Zlotta on the Maturation of Trimodality Therapy
Alexandre Zlotta, MDMuscle Invasive Urothelial Carcinoma | May 15, 2025
Dr. Zlotta discusses the current state and future of bladder-sparing therapy in MIBC, including how to best select patients.
From VEGF to HIF-2 Targeting Drugs: Dr. James Brugarolas’ Journey to Transforming Kidney Cancer Treatment
From VEGF to HIF-2 Targeting Drugs: Dr. James Brugarolas’ Journey to Transforming Kidney Cancer Treatment
James “Jim” Brugarolas, MD, PhDRenal Cell Carcinoma | April 22, 2025
Dr. Brugarolas reflects on his lab's role in developing HIF-2 inhibitors and his ongoing work to improve patient outcomes.
Bladder-Sparing Innovations in MIBC: Dr. Elizabeth Plimack on the RETAIN Approach and Its Future
Bladder-Sparing Innovations in MIBC: Dr. Elizabeth Plimack on the RETAIN Approach and Its Future
Elizabeth Plimack, MD, MS, FASCOMuscle Invasive Urothelial Carcinoma | March 17, 2025
Dr. Plimack details RETAIN, from early findings with neoadjuvant ddMVAC to the evolution of RETAIN-1 and RETAIN-2.
Precision in Prostate Cancer: Dr. Amir Lebastchi on Tailoring Focal Therapy for Optimal Outcomes
Precision in Prostate Cancer: Dr. Amir Lebastchi on Tailoring Focal Therapy for Optimal Outcomes
Akhil Abraham Saji, MDLocalized | January 14, 2025
Drs. Saji and Lebastchi explore focal therapy, covering its historical evolution, techniques, and energy modalities.
Ahmed E. Ghazi – Revolutionizing and Scaling Surgical Training Through Simulation Models
Ahmed E. Ghazi – Revolutionizing and Scaling Surgical Training Through Simulation Models
David Ambinder, MDLocalized | January 6, 2025
Dr. Ghazi is recognized as a pioneer in patient-specific surgical simulation, using state-of-the-art techniques in surgery.
Merging Clinical Trials With the Clinic: Bladder Cancer Therapeutic Advances With Dr. Brad McGregor
Merging Clinical Trials With the Clinic: Bladder Cancer Therapeutic Advances With Dr. Brad McGregor
Brad McGregor, MDMuscle Invasive Urothelial Carcinoma | August 14, 2024
Dr. Brad McGregor shares exciting developments in the MIBC space and the challenges facing the field of GU oncology.

Knowledge Hubs

Curated clinical content based on conditions, therapies, and technologies

Prostate Cancer
Prostate Cancer
CRPC
CRPC
Localized
Localized
Prostate Cancer Diagnostics
Prostate Cancer Diagnostics
RLT
RLT
mHSPC/mCSPC
mHSPC/mCSPC
Renal Cell Carcinoma
Renal Cell Carcinoma
Localized Renal Cell Carcinoma
Localized Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
nccRCC
nccRCC
Renal Cell Carcinoma Diagnostics
Renal Cell Carcinoma Diagnostics
Testicular, Penile, and Rare Malignancies
Testicular, Penile, and Rare Malignancies
Urothelial Carcinoma
Urothelial Carcinoma
Advanced Urothelial Carcinoma
Advanced Urothelial Carcinoma
Muscle Invasive Urothelial Carcinoma
Muscle Invasive Urothelial Carcinoma
Non-Muscle Invasive Urothelial Carcinoma
Non-Muscle Invasive Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Urothelial Carcinoma Diagnostics
Urothelial Carcinoma Diagnostics
Prostate Cancer
Prostate Cancer
CRPC
CRPC
Localized
Localized
Prostate Cancer Diagnostics
Prostate Cancer Diagnostics

The Uromigos

Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD

Episode 413: The Uromigos Score for Advanced Prostate Cancer
Episode 413: The Uromigos Score for Advanced Prostate Cancer
Returning guests Drs. Gillessen and Sweeney discuss the value of treatments for advanced prostate cancer.
# Posted on May 13, 2025
# Uromigos-Prostate Cancer
Episode 412: AUA 2025 - TAR-200 Monotherapy in BCG-Unresponsive NMIBC From SunRISe-1n
Episode 412: AUA 2025 - TAR-200 Monotherapy in BCG-Unresponsive NMIBC From SunRISe-1n
Dr. Joe Jacob joins the show to discuss the longer-term follow up of this cohort from SunRISe-1.
# Posted on May 6, 2025
# Uromigos-Bladder Cancer
Episode 411: Live From EIKCS in Amsterdam - RCC Highlights
Episode 411: Live From EIKCS in Amsterdam - RCC Highlights
Dr. Viktor Grünwald joins the show to discuss the new data session from the European International Kidney Cancer Symposium.
# Posted on May 6, 2025
# Uromigos-Kidney Cancer

Conference Coverage

Live meeting highlights

Dr. David Canes on WellPrept - Boosting Patient Education and Improving Care
David Canes, MDUrothelial Carcinoma | May 7, 2025
Dr. Canes discusses the formation of the WellPrept delivery platform and how it aims to boost patient education.
View More
Guidelines for Measuring Patient Outcomes and Quality Improvements in GU Oncology
Mohummad Siddiqui, MDUrothelial Carcinoma | May 5, 2025
Mohummad Siddiqui, MD, discusses his work with the Commission on Cancer and their development on standards of care.
View More
ctDNA in GU Oncology: History, Current Studies, and Benefits
John Sfakianos, MDUrothelial Carcinoma Diagnostics | May 5, 2025
John P. Sfakianos, MD, discusses the history and use of ctDNA in the GU oncology field.
View More
cT1a and cT1b-cT2 RCC: Who is at Risk of Upstaging to pT3a?
Victor Sandoval, MD, MScLocalized Renal Cell Carcinoma | May 5, 2025
Dr. Sandoval chats with David Ambinder, MD, on the upstaging of cT1b and cT2 tumors to pT3a.
View More

Video Insights

Clinical discussions with experts in the field

Network Websites

Blood Cancers Today provides hematologists and oncologists with news, education, and research relevant to their patients and practices. Featuring the latest clinical updates from all facets of the specialty, it offers thought-provoking insights and exclusive interviews from experts in the field.

MashupMD is an innovative medical news and social media aggregator. The platform is optimized to deliver rapid access to the latest headlines in health care and collections of key medical content based on what health care professionals around the world are reading and sharing.

Cancer Nursing Today delivers critical news, research, and commentary to support oncology nurses throughout their education and careers. Its goal is to advance oncology treatments and care practices and promote the nurse’s role in enhanced patient outcomes and quality of life.

DocWire News is a leading source of medical industry news for health care professionals, featuring breaking news, expert commentary, research analysis, and conference highlights. It covers a comprehensive range of clinical specialties, including cardiology, oncology, neurology, and more.

Urban Health Today is the leading independent news source that provides urban health care professionals with relevant research and policy developments that impact patients and their practices. Its coverage focuses on clinical, social, and environmental health disparities.

Powered by DocWire News

GI Oncology Now is the leading medical news resource for practicing oncologists and health care providers treating gastrointestinal malignancies, offering the latest study data and research breakthroughs related to colorectal, gastric, liver, pancreatic, and esophageal cancers.

Heme Today produces the latest news and research for hematologists and oncologists focused on blood disorders such as clotting, red and white blood cell, and iron disorders, including conference highlights, late-breaking research, interviews with leaders in the field, and more.

A medical news property for practicing oncologists treating lung malignancies, Lung Cancers Today features breaking news, commentary, expert interviews, and data analysis to inform providers on the latest research and most effective clinical practices in the lung cancers space.

Nephrology Times delivers the latest news in nephrological treatments and technologies, curating content from clinical trials, conference highlights, and perspectives from key opinion leaders, with the goal of better informing care decisions and improving patient outcomes.

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Contributors and Partners

    Editorial Policy

    Advertising

    Connect

    eNewsletters

    Calendar

    Contact Us

    Contribute

    Our Network

    MashupMD

    Cancer Nursing Today

    Urban Health Today

    Blood Cancers Today

    DocWire News

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |